Lung Cancer Therapy Market could be worth US$ 31,018.32 million by 2030,says Premium Market Insights

Lung Cancer Therapy Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa) The lung cancer therapy market is expected to grow from US$ 31,018.32 million in 2022 to US$ 80,493.84 million by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.

Get PDF Sample Report + All Related Table and Graphs @: https://www.premiummarketinsights.com/sample/TIP00083401?utm_source=OpenPR&utm_medium=10823

Competitive Landscape: Lung Cancer Therapy Market:
Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

Medtronic PLC
RF Medical Co Ltd
Johnson & Johnson
Merck KGaA
Sun Pharmaceutical Industries Ltd
Bioventus Inc
Meiji Seika Pharma Co Ltd
Advanz Pharma Corp
Olympus Corp
Bottom of Form

Chapter Details of Lung Cancer Therapy Market:
Part 01: Executive Summary
Part 02: Scope of The Report
Part 03: Lung Cancer Therapy Market Landscape
Part 04: Lung Cancer Therapy Market Sizing
Part 05: Lung Cancer Therapy Market Segmentation by Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers and Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis

Interested in Purchasing this Report? Click here @ https://www.premiummarketinsights.com/buy/TIP00083401?utm_source=OpenPR&utm_medium=10823

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sushant More
SE-mail: sales@permiummarketinsights.com
Phone: +1-646-491-9876

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.

This release was published on openPR.